Anti-Mouse IL-6 - 25 µg

ICC, IHC FF, N, WB

IL-6

Next Day Ambient

IL-6 is a pleotropic 26 kD protein that can act as both a pro-inflammatory cytokine and an anti-inflammatory myokine, a form of cytokine produced in muscle cells that participates in tissue regeneration and repair, maintenance of healthy bodily functioning, and homeostasis within the immune system. IL-6 plays a part in the immune, endocrine, nervous, and hematopoietic systems, in addition to bone metabolism, regulation of blood pressure and inflammation. Osteoblasts secrete IL-6 to stimulate osteoclast formation. Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-inflammatory cytokine. Furthermore, IL-6 is an important mediator of fever and of the acute phase response which is the body's rapid attempt to restore homeostasis after tissue injury, infection, neoplastic growth, or immunological disturbance. In addition, IL-6 can be released into circulation in response to various stimuli including PAMPs (pathogen-associated molecular patterns) and cortisol, a hormone produced by the human body under psychologically stressful conditions. In its role as an anti-inflammatory myokine, IL-6 precedes the appearance of other cytokines in the circulation, is notably elevated with exercise, and is mediated by both its inhibitory effects on TNF-α and IL-1, and activation of IL-1ra and IL-10. IL-6 signals through a cell-surface type I cytokine receptor complex formed by the binding of IL-6 to IL-6R, forming a binary complex, which in turn combines with GP130 to transduce extracellular signaling by the activation STAT3. Hence, it is thought that blocking the interaction between IL-6 and GP130 may have therapeutic potential via the inhibition of the IL-6/GP130/STAT3 signaling pathway. Moreover, IL-6 initiates the inflammatory and auto-immune processes in many diseases such as diabetes, atherosclerosis, depression, Alzheimer's disease, rheumatoid arthritis, cancer, and various others. Thus, there is an interest in the therapeutic potential of anti-IL-6 mAbs.

Immunohistochemistry: Suitable for use at concentration of 5-15 µg/mL.
Immunocytochemistry: Suitable for use at concentration of 5-15 µg/mL.
Neutralization:Measured by its ability to neutralize IL‑6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. Nordan, R.P. and M. Potter (1986) Science 233:566. The Neutralization Dose (ND₅₀) is typically 0.01-0.03 µg/mL in the presence of 0.25 ng/mL Recombinant Mouse IL‑6.

Other Molecules

AB_2830559

< 0.1 EU/µg as determined by the LAL method

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.